Effectiveness of Parenteral Glutamine on Methotrexate-induced Oral Mucositis in Children with Acute Lymphoblastic Leukemia

Yu Hsiang Chang, Ming Sun Yu, Kang Hsi Wu, Mao Chou Hsu, Yee Hsuan Chiou, Han Ping Wu, Ching Tien Peng, Yu Hua Chao

    Research output: Contribution to journalArticlepeer-review

    6 Scopus citations

    Abstract

    High-dose methotrexate (HDMTX) is important for children with acute lymphoblastic leukemia (ALL). There is no effective treatment for patients with oral mucositis, which is a major side effect associated with HDMTX. Here, we reviewed the medical records of patients younger than 18 yr with newly diagnosed ALL in our hospitals from 2002 to 2013. According to the nationwide protocol (TPOG-ALL-2002), each patient received four courses of HDMTX (2.5 or 5 g/m2) during consolidation therapy. HDMTX courses with glutamine therapy were as the glutamine group, and intravenous glutamine (0.4 g/kg/day) was started within 48 h after the initiation of HDMTX for 3 consecutive days. HDMTX courses without glutamine were as the control group. A total of 347 HDMTX courses were administrated in the 96 children with ALL during the study period. The incidence of oral mucositis was significantly lower in the glutamine group than in the control group (3.8% vs. 17.6%; P = 0.004). In the glutamine group, no patients suffered from severe oral mucositis. No severe adverse effects associated with glutamine administration were noted. Accordingly, parenteral glutamine appears to be feasible and safe to prevent oral mucositis in patients receiving HDMTX.

    Original languageEnglish (US)
    Pages (from-to)746-751
    Number of pages6
    JournalNutrition and cancer
    Volume69
    Issue number5
    DOIs
    StatePublished - Jul 4 2017

    ASJC Scopus subject areas

    • Medicine (miscellaneous)
    • Oncology
    • Nutrition and Dietetics
    • Cancer Research

    Fingerprint Dive into the research topics of 'Effectiveness of Parenteral Glutamine on Methotrexate-induced Oral Mucositis in Children with Acute Lymphoblastic Leukemia'. Together they form a unique fingerprint.

    Cite this